Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05917431 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 23, 2023 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (SBRT) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic hepatocellular carcinoma (HCC). The main question to answer is: Whether combing SBRT with immunotherapy and targeted therapy could prolong PFS. Participants will receive SBRT to all visible lesions and concurrent systemic immunotherapy and targeted therapy.
Trial Details
NCT Number NCT05917431
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions
(from sponsor)		 Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Enrollment 39 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov